SYMJEPI Photo 1
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
March 21, 2022 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
March 14, 2022 08:17 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that on March 11, 2022, the Data Safety Monitoring Board (DSMB) overseeing the Phase...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
March 04, 2022 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. “Dick has...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
February 28, 2022 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo...
Adamis Pharmaceuticals logo
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2022 16:05 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
February 07, 2022 09:17 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
January 10, 2022 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
December 01, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
November 23, 2021 14:39 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 22, 2021 16:47 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...